Setback for AZ’ asthma drug as trial misses endpoint

by | May 10, 2017 | | 0

AstraZeneca’s tralokinumab has failed to significantly reduce the rate of annual exacerbations in patients with uncontrolled asthma taking part in a late-stage trial.

Read More